Tevogen Bio Holdings Inc
TVGNW0.049USD
-0.000-0.81%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Tevogen Bio Holdings Inc Unternehmen
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Unternehmensinformationen
Unternehmens-codeTVGNW
Name des UnternehmensTevogen Bio Holdings Inc
IPO-datumNov 04, 2021
Gegründet am2024
CEODr. Ryan Saadi, M.D.
Anzahl der mitarbeiter- -
WertpapierartCompany Warrant
Geschäftsjahresende- -
Addresse15 Independence Boulevard, Suite 410
StadtWARREN
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl07059
Telefon16468078832
Websitehttps://tevogen.com/
Unternehmens-codeTVGNW
IPO-datumNov 04, 2021
Gegründet am2024
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
--
--
Mr. Jeffrey Feike
Mr. Jeffrey Feike
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Susan M. Podlogar
Ms. Susan M. Podlogar
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Victor Sordillo
Mr. Victor Sordillo
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ryan Saadi, M.D.
Dr. Ryan Saadi, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Curtis Patton
Dr. Curtis Patton
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Keow Lin (Lindee) Goh
Dr. Keow Lin (Lindee) Goh
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Surendra (Suren) Ajjarapu
Mr. Surendra (Suren) Ajjarapu
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Sadiq Khan
Mr. Sadiq Khan
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
--
--
Mr. Jeffrey Feike
Mr. Jeffrey Feike
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Susan M. Podlogar
Ms. Susan M. Podlogar
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Victor Sordillo
Mr. Victor Sordillo
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ryan Saadi, M.D.
Dr. Ryan Saadi, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Sun, Feb 23
Update-Zeit: Sun, Feb 23
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Other
100.00%
Aktionärsstatistik
Aktionäre
Anteil
Other
100.00%
Art
Aktionäre
Anteil
Other
100.00%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
65
14.15M
0.00%
-3.01M
2024Q4
69
14.15M
0.00%
-3.24M
2024Q3
73
15.05M
0.00%
-2.82M
2024Q2
74
15.32M
0.00%
-2.48M
2024Q1
73
15.60M
0.00%
-2.66M
2023Q4
71
16.67M
0.00%
-144.22K
2023Q3
71
15.71M
0.00%
-753.59K
2023Q2
71
15.36M
0.00%
-1.08M
2023Q1
71
15.53M
0.00%
-387.68K
2022Q4
61
15.25M
0.00%
+1.25M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Highbridge Capital Management, LLC
2.57M
0%
+500.93K
+24.23%
Dec 31, 2024
Parallax Volatility Advisers, L.P.
1.68M
0%
-479.65K
-22.17%
Dec 31, 2024
Fourworld Capital Management LLC
1.45M
0%
--
--
Dec 31, 2024
Corbin Capital Partners, L.P.
1.16M
0%
--
--
Dec 31, 2024
Calamos Advisors LLC
1.00M
0%
--
--
Dec 31, 2024
Greenland Capital Management LP
703.03K
0%
--
--
Dec 31, 2024
Polar Asset Management Partners Inc.
700.00K
0%
-17.31K
-2.41%
Dec 31, 2024
MMCAP Asset Management
650.00K
0%
--
--
Dec 31, 2024
Linden Advisors L.P.
650.00K
0%
--
--
Dec 31, 2024
Atalaya Capital Management LP
300.00K
0%
--
--
Jun 30, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten